ePrints

The Role of Hormonal therapy in Gynaecological Cancers – Current Status and Future Directions

Lookup NU author(s): Professor Richard Edmondson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Many gynaecological cancers, including epithelial and stromal ovarian cancers, endometrial carcinomas as well as some gynaecological sarcomas, in particular endometrial stromal sarcomas, express oestrogen and/ or progesterone receptors. Hormonal therapy, typically progestagens or tamoxifen is commonly prescribed to patients with potentially hormone sensitive recurrent or metastatic gynaecological cancers with very variable response rates and clinical benefit reported. Aromatase inhibitors are now widely used to treat post-menopausal women with hormone receptor positive breast cancers as they have greater activity than tamoxifen and are generally better tolerated. The role of aromatase inhibitors in gynaecological cancers is uncertain and has not been well studied although they do appear to be active. The current evidence to support the use of hormonal therapies including aromatase inhibitors in gynaecological cancers will be reviewed and the gaps in our knowledge highlighted

Publication metadata

Author(s): Sjoquist KM, Martyn J, Edmondson RJ, Friedlander ML

Publication type: Article

Publication status: Published

Journal: International Journal of Gynecological Cancer

Year: 2011

Volume: 21

Issue: 7

Pages: 1328-1333

Print publication date: 01/10/2011

ISSN (print): 1048-891X

ISSN (electronic): 1525-1438

Publisher: Lippincott Williams & Wilkins

URL: http://dx.doi.org/10.1097/IGC.0b013e31821d6021

DOI: 10.1097/IGC.0b013e31821d6021

PubMed id: 21720258

Altmetrics

Share